Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsChinmay Shukla has spoken on 4 earnings calls and 6 other investor events across 1 company, most recently for BridgeBio Pharma, Inc. on September 9, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“Derek, thank you for hosting us, and thanks to the investors for joining us. We're excited to speak to you today and excited for all our conversations.”
“Good afternoon, everyone, and thank you for joining BridgeBio Pharma's second quarter 2026 earnings call. I'm Chinmay Shukla, Senior Vice President, Strategic Finance.”
“So we're incredibly pleased to see the strong growth of the ATTRCM market. Maybe I'll just break about the market into the two segments, first line and second line.”
“Yeah, and just to build on what Tom said, so beyond the $8 billion, we have expansion indications, hypoparathyroidism, and calarid is being investigated there. That probably adds another couple billion dollars to our peak year cells.”
“Yeah, and just to build on what Tom said, so beyond the $8 billion, we have expansion indications, hypoparathyroidism, and calarid is being investigated there. That probably adds another couple billion dollars to our peak year cells.”
Source not stated
Biotechnology · Healthcare
